Neko Health raises $700m Series C ahead of US launch

LONDON/STOCKHOLM - WEDNESDAY JULY 15, 2026 Founded by Spotify's Daniel Ek and Hjalmar Nilsonne, Neko Health, the health technology company redefining how people understand and act on their health, today announced the completion of its $700 million Series C funding round.

The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst and Lakestar, alongside new backers including Liberty City Ventures, Positive Sum, and BDT & MSD. As part of the round, David Ofer of O.G. Venture Partners will join the Board of Directors, subject to regulatory approval. The fundraise follows a $260m Series B in January 2025.

"Over the past eighteen months, Neko Health has demonstrated remarkable innovation and growth, attacking one of the largest markets in the world with breakthrough technology, proven consumer demand, and a clear path to global scale. We believe this is one of the most important healthcare companies of our generation, and we're proud to deepen our partnership as they continue to reimagine prevention."

"We've known Hjalmar, Daniel and the founding team at Neko Health for years and have deep respect for their vision to redefine health for more than just the privileged few, on a global scale. They execute at a level few can match."

The funding round also saw participation from Ari Emanuel, Claudia Schiffer and Sir Matthew Vaughn, Danny Meyer, Jimmy Iovine, Maria Sharapova, Mark Zuckerberg and Priscilla Chan, Thierry Henry, Tim Ferriss and will.i.am, joining existing investors including Alexis Ohanian from Seven Seven Six, Alex Tew and Michael Acton-Smith from Calm, Gary Vaynerchuk, Jessie Inchauspé, Katie Haun, Raj Shamani, Steven Bartlett, Zoë Saldaña and Marco Perego-Saldaña.

"For more than 20 years, I've tracked every metric imaginable to optimize health and performance. It’s expensive, complicated, and fragmented. I’ve invested in Neko because they offer beautiful simplicity, and only simplicity scales: you get a high-definition map of your biology in less than 60 minutes, explained by an unhurried doctor, all in one location and for £299. No one else can do this. And believe me, as I’ve toured their R&D lab in Sweden: there’s a lot more coming,” says Tim Ferriss, bestselling author of The 4-Hour Body, which introduced millions to data-driven personal health, including continuous glucose monitors, DEXA, and other technologies.

At the heart of Neko’s offering is the Neko Health Scan. It is a 60-minute, comprehensive, non-invasive, and radiation-free health assessment that captures millions of health data points, priced at £299 in the UK and 2,750 SEK in Sweden. Using proprietary sensors alongside blood analysis, the scan assesses skin health, including moles and marks, biomarkers to identify pre-diabetes risk, as well as blood abnormalities, and risk factors linked to metabolic syndrome, stroke, and heart attack. Results are delivered on-site within minutes and discussed during an in-person consultation with a medical professional, providing members with personalized and actionable health findings.

Today's news comes three weeks after Neko's most significant scan advancement to date. The addition of body composition measures, captured in seconds during the scan, and clinician review of wearable data, is now live across all clinics – giving members an even more detailed picture of their health both in the moment and between visits. This is the latest step in a program of continuous innovation, made possible by Neko owning every part of its tech stack in-house.

Neko Health builds technology in-house, including hardware, software, and consumer experience. This vertical integration is not incidental; it is the foundation that allows Neko Health to control the experience from start to finish, to move faster and to improve continuously.

Last month, Neko opened its latest clinic in Stockholm, built around the next generation of Neko-engineered medical devices, Derma-2, Echo-2, and Spectrum-2, each upgraded to capture a greater volume and higher fidelity of health signals across skin, heart, and circulation, with increased automation freeing up clinical staff to focus on member care. This next-generation hardware will be rolled out across all Neko clinics in the next few months.

"This funding is a strong vote of confidence in what we set out to do when we opened our first clinic three years ago: a completely new healthcare experience designed to keep people healthy, catch problems early and help prevent disease before it even starts. With this round, we're taking that mission to the US for the first time, while continuing to invest in the research and technology that make prevention possible at scale. The clearest proof is in our members: the vast majority of our members return after their first scan, and when they do, their health markers move in the right direction."

The news comes as healthcare systems on both sides of the Atlantic move decisively toward prevention. In the UK, NHS England’s latest planning framework sets out an explicit shift from sickness management to proactive population health. In the US, new national dietary guidelines and a wave of employer health strategies reflect growing recognition that chronic disease, responsible for the vast majority of healthcare spend, is better addressed before it develops than after.

Since launching in February 2023, Neko Health has expanded its footprint in Sweden and the UK, including Manchester, Birmingham and multiple locations in London (Marylebone, Spitalfields, Covent Garden, Victoria). Over 350,000 people have registered for a Neko Health Scan, and more than 100,000 members have already experienced one. On average, 75% of members book and prepay a scan for the following year at the end of their appointment.

From its latest health data, early detection is translating into measurable health improvements for returning members. Neko Health found that three in four returning members with previously identified severe or life-threatening conditions were in good health or had their condition under control. Overall, five of seven key biomarkers showed statistically significant improvement between Scan 1 and Scan 2.

By signing up to the waitlist today, people can be guaranteed first access to the New York clinic as Neko Health continues to expand to further locations and cities: https://www.nekohealth.com

For more information please reach out to: press@nekohealth.com